Gastric adenocarcinoma is the second leading cause of death due to cancer in the world and in advanced stages the prognosis is poor even with current therapies. Over-expression of HER-2/neu has been seen in several cancers such as gastric cancer and its expression is associated with poor prognosis. The aim of this study is to evaluate the over-expression of HER-2/neu in gastric biopsy samples of patients with gastric carcinoma diagnosis; and to evaluate its probable relationship with clinical and pathological findings. The over-expression of HER-2/neu was examined retrospectively by immunohistochemistry method in 60 paraffin embedded samples collected in Babol, Iran, between 2010 and 2011. The over-expression of HER-2/neu has been observed in 6 patients (10%) and this over-expression was greater in the intestinal type of gastric adenocarcinoma than the diffuse type (12% vs. 6%); however, no statistically significant correlation between HER-2/neu expression and subtype, degree of differentiation, tumor type and age was observed. This over-expression was greater in differentiated types than undifferentiated types (18% vs. 5%).
HER-2/neu Marker Examination in Gastric
In normal condition, ligand binding with specific growth factor leads to temporary activation of kinase and then, dimerization and tyrosine phosphorylation of several substrates, which are part of messaging cascade, will happen quickly.
Oncogenic types of these receptors are capable of dimerization and innate activity without binding to growth factor; therefore, mutated receptors continuously transmit mutagenic messages into cells (2, 6 ).
In the last two decades, over-expression of HER-2/neu in different types of cancers has been seen, so that the over-expression of this marker was reported in about 10-34% of advanced breast cancer (14) .
Also, in the different parts of the world, studies on over-expression of HER-2/neu in gastric adenocarcinoma show that it goes together with poor prognosis, increased invasion and metastasis.
Likewise, this over-expression is more common in gastric adenocarcinoma than diffuse carcinoma subtype (15) (16) .
It also has been demonstrated that in gastric adenocarcinoma, expression of HER-2/neu is an independent prognostic factor for survival and prognosis (17) (18) (19) . (Figures 1-4 ).
Then cases with 0 and +1 scores were supposed as negative and+3 as positive (23) . +2 cases which should be supposed as equivocal, due to impossibility of doing HER-2/FISH (Fluorescence in situ Hybridization) were supposed as negative in this study.
Statistical analyzes
Data were analyzed using SPSS 17 software and X2
tests, Fisher more precise test and T-test. P< 0.05 was supposed to be statistically significant.
Results
In this study, the age range of patients was between 35 to 94 years (average 70.9) and the male to female ratio was 2.57 (44 men and 16 women). The expression of HER-2/neu in intestinal type was more than diffuse type (12% vs. 6%).
Despite these differences, there was no statistically significant difference (P> 0.05). This finding is in contrast with most studies conducted in other areas.
For example, in a study conducted by Park et al. The present study has also shown that the expression of HER-2/neu in men is more than women. However, the difference is not statistically significant (P> 0.05), but this study is in accordance with most previous reports (10, 28) although, more studies with larger sample sizes, may show a significant difference in this area.
The present study has shown that the expression of HER-2/neu in older patients (≥ 65 years) is more, but this difference is not statistically significant (P> 0.05). This is in accordance with a previous study performed in Iran (27) , but then again, more studies in this area with larger sample sizes may show a significant difference.
We observed an over-expression of HER-2/neu in 10 % of patients with gastric adenocarcinoma in Babol. Since +2 cases in IHC staining which should normally be evaluated by FISH method were considered as negative cases, it is likely that the expression of this marker is more than 10% and therefore, these people might receive monoclonal antibodies (Trastuzumab) therapy. 
